Sotagliflozin

Cat. No. EXTZ-633

Lot. No. (See product label)

Introduction

Description

Sotagliflozin is an innovative dual inhibitor of sodium-glucose co-transporter 2 (SGLT2) and sodium-glucose co-transporter 1 (SGLT1), primarily used for the treatment of type 2 diabetes. Through its unique dual mechanism of action, it not only inhibits SGLT2 in the kidneys to reduce glucose reabsorption but also inhibits SGLT1 in the intestines to decrease glucose absorption, thereby effectively controlling blood sugar levels. Function Sotagliflozin helps lower blood sugar by increasing glucose excretion in urine and reducing glucose absorption in the intestines. Additionally, studies have shown that SGLT2 inhibitors may offer cardiovascular protective benefits, such as reducing the risk of heart failure and improving cardiovascular outcomes, which gives Sotagliflozin potential multiple benefits in diabetes treatment.

Product Information

Form

Powder

Purity

99.00%